March 9, 2006 (San Francisco) — The largest and arguably most complex risk-management program ever undertaken by the US Food and Drug Administration is sparking a commensurate measure of controversy — ...

More than a month after the launch of the new iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program, the operation still isn't running smoothly for many dermatologists, pharmacists, and ...

Please provide your email address to receive an email when new articles are posted on . Researchers, along with the American Academy of Dermatology, have organized an iPLEDGE Workgroup to advocate for ...

Please provide your email address to receive an email when new articles are posted on . The FDA has issued a notification to isotretinoin manufacturers to modify the iPledge Risk Evaluation and ...